O2h to do ‘heavy lifting’ as part of synthetic chemistry collaboration with Cedilla

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Pinkypills)
(Image: Getty/Pinkypills)

Related tags: Synthetic chemistry, Drug discovery

Cedilla Therapeutics and o2h Discovery have announced a multi full-time-equivalent (FTE) expansion to their synthetic chemistry collaboration.

Cambridge, MA-based Cedilla Therapeutics is ‘discovering and exploiting’ insights into protein stability, according to the company, and generating therapeutics that degrade protein targets.

Sunil Shah, CEO of o2h Discovery, said it will be providing “the heavy lifting in medicinal chemistry and biological profiling,”​ as part of the collaboration.

“The goal is to achieve a drug candidate,” ​he told us.

Additionally, Shah noted that Karyopharm, for which o2h provides similar support, recently received US Food and Drug Administration (FDA) approval for oral Xpoviotm (selinexor), in combination with dexamethasone, as a new treatment for relapsed or refractory multiple myeloma.

An integrated drug discovery platform, o2h Discovery operates from its research center in India and The Mill SciTech Park, in Cambridge, UK.

The company, founded in 2005, also has launched its proprietary ‘AI ​Chemistry in the Cloud’ (AI-CITC) application, which enables communication between various scientific stakeholders.

Related news

Related products

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more